期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

EZH2基因沉默逆转卵巢上皮性癌细胞顺铂耐药性的实验研究 被引量：2

原文传递
导出
摘要 EZH2基因是果蝇zeste基因增强子的人同源物，作为一种转录抑制因子参与基因沉默，在细胞生长调控中发挥着重要作用。研究发现，EZH2基因可以抑制相关癌基因的活性，在前列腺癌、乳腺癌。和胰腺癌等多种恶性肿瘤组织中高表达，促进肿瘤生长、侵袭和转移。然而迄今为止，对EZH2基因参与卵巢上皮性癌（卵巢癌）化疗耐药及其机制的研究鲜见报道。本研究应用真核质粒载体介导的RNA干扰技术抑制EZH2基因的表达，探讨EZH2基因沉默后逆转卵巢癌耐药细胞株A2780／DDP对顺铂耐药的可能作用机制，为EZH2基因在卵巢癌耐药的基因治疗提供实验基础。
作者 胡沙 李智敏 王静 唐慧娟 于利利 王泽华
机构地区 华中科技大学同济医学院附属协和医院妇产科
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2010年第3期232-234,共3页 Chinese Journal of Obstetrics and Gynecology
基金 国家自然科学基金（30901585）
关键词 EZH2基因 卵巢上皮性癌 顺铂耐药性 基因沉默 实验研究 癌细胞 逆转 卵巢癌耐药
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Simon JA,Lange CA.Roles of the EZH2 histone methyltransferase in cancer epigenetics.Mutat Res,2008,647:21-29.
  • 2宋力,崔小健,苏大军,谭国良.前列腺癌组织EZH2基因的表达及其意义[J].第四军医大学学报,2006,27(13):1193-1195. 被引量：3
  • 3Gonzalez ME,Li X,Toy K,et al.Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1.Oncogene,2009,28:843-853.
  • 4Ougolkov AV,Bilim VN,Billadeau DD.Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.Clin Cancer Res,2008,14:6790-6796.
  • 5Bird A.Perception of epigenetics.Nature,2007,447:396-398.
  • 6Balch C,Huang TH,Brown R,et al.The epigenetics of ovarian cancer drug resistance and resensitization.Am J Obstet Gynecol,2004,191:1552-1572.
  • 7Humeniuk R,Mishra PJ,Bertino JR,et al.Molecular targets for epigenetic therapy of cancer.Curr Pharm Biotechnol,2009,10:161-165.
  • 8Fujii S,Ochiai A.Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.Cancer Sci,2008,99:738-746.
  • 9Hinz S,Kempkensteffen C,Christoph F,et al.Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urolhelial carcinoma of the bladder.J Cancer Res Clin Oncol,2008,134:331-336.
  • 10Abbosh PH,Montgomery JS,Starkey JA,et al.Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.Cancer Res,2006,66:5582-5591.

二级参考文献8

  • 1Arisan S,Buyuktuncer ED,Palavan-Unsal N,et al.Increased expression of EZH2,a polycomb group protein in bladder carcinoma[J].Urologia,2005,75:252-257.
  • 2Hobert O,Jallal B,Ullrich A.Interaction of Vav wit h ENX-1,a putativet ranscriptional regulator of homeobox gene expression[J].Mol Cell Biol,1996,16(6):3066-3073.
  • 3Cardoso C,Mignon C,Hetet G,et al.The human EZH2 gene:genomic organisatin and revised mapping in 7q35 within the critical region for malignant myeloid disorders[J].Eur J Hum Genetics,2000,8:174.
  • 4Kuzmichev A,Jenuwein T,Tempst P,et al.Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3[J].Mol Cell,2004,14(2):183-193.
  • 5Varambally S,Dhanasekaran SM,Ming H,et al.The poly2comb group protein EZH2 is involved in progression of prostate cancer[J].Nature,2002,419:624-627.
  • 6Raaphorst FM,van Kemenade FJ,Blokijl T,et al.Expression of BMI-1 and EZH2 polycomb group genes in reed-sternberg cells of Hodgkins disease[J].Am J Pathol,2000,157:709-712.
  • 7Raaphorst FM,Meijer CJ,Fieret E,et al.poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene[J].Neoplasia,2003,5(6):481-488.
  • 8Lun-Xiu Qin Zhao-You Tang,Liver Cancer Institute and Zhongshan Hospital,Fudan University,Shanghai,China.The prognostic significance of clinical and pathological features in hepatocellular carcinoma[J].World Journal of Gastroenterology,2002,8(2):193-199. 被引量：77

共引文献7

同被引文献20

  • 1Szakacs G, Paterson JK, Ludwig JA, et al. Targeting muhidrug resistance in cancer[J]. Nat Rev Drug Discov, 2006,5(3) :219 -234.
  • 2Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics [ J ]. Mutat Res,2008,647 ( 1 - 2 ) :21 - 29.
  • 3Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin [J]. Crit Rev Oncol Hematol, 2007,63(1 ):12-31.
  • 4Simon JA, Lange CA, Roles of the EZH2 histone methyhransferase in cancer epigeneties[ J ]. Mutat Res, 2008,647 ( 1 - 2 ) :21 - 29.
  • 5Wagener N, Holland D, Bulkescher J,et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells[ J ]. lnt J Cancer, 2008,123 (7) : 1545 - 1550.
  • 6Lu C, Han HD, Mangala LS,et al. Regulation of tumor angiogenesis byEZtt2[J]. Cancer Cell, 2010 ,18(2) :185 -197.
  • 7Varambally S, Dhanasekaran SM, Zhou M ,et al. The polycomb group prolein EZH2 is involved in progression of proslate cancer[ J ].Nature, 2002,419 ( 6907 ) :624 - 629.
  • 8Kleer CG, Cao Q, Varambally S,et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells[J]. Proc Natl Acad Sci U S A, 2003,100(20) :11606 -11611.
  • 9Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and ehemoresistanee by the his/one methyltransferase enhancer of zeste homologue 2 [ J ]. 2008,14 ( 21 ) :6790 - 6796.
  • 10Hu S, Yu L, Li Z,et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo [J]. Cancer Biol Ther, 2010,10(8) : 788 -795.

引证文献2

二级引证文献2

中华妇产科杂志
2010年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部